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Introduction: PET imaging of amyloid-β (Aβ) in vivo holds promise for aiding in earlier diagnosis and intervention
in Alzheimer’s disease (AD) and mild cognitive impairment. AD-like Aβ pathology is a common comorbidity in
patients with idiopathic normal pressure hydrocephalus (iNPH). Fifty patients with iNPH needing ventriculo-
peritoneal shunting or intracranial pressure monitoring underwent [18F]flutemetamol PET before (N = 28) or
after (N = 22) surgery. Cortical uptake of [18F]flutemetamol was assessed visually by blinded reviewers, and also
quantitatively via standard uptake value ratio (SUVR) in specific neocortical regions in relation to either cerebellum
or pons reference region: the cerebral cortex of (prospective studies) or surrounding (retrospective studies) the
biopsy site, the contralateral homolog, and a calculated composite brain measure. Aβ pathology in the biopsy
specimen (standard of truth [SoT]) was measured using Bielschowsky silver and thioflavin S plaque scores, percentage
area of grey matter positive for monoclonal antibody to Aβ (4G8), and overall pathology impression. We set out to
find (1) which pair(s) of PET SUVR and pathology SoT endpoints matched best, (2) whether quantitative measures of
[18F]flutemetamol PET were better for predicting the pathology outcome than blinded image examination (BIE),
and (3) whether there was a better match between PET image findings in retrospective vs. prospective studies.
Results: Of the 24 possible endpoint/SoT combinations, the one with composite-cerebellum SUVR and SoT based
on overall pathology had the highest Youden index (1.000), receiver operating characteristic area under the curve
(1.000), sensitivity (1.000), specificity (1.000), and sum of sensitivity and specificity for the pooled data as well as for the
retrospective and prospective studies separately (2.00, for all 3). The BIE sum of sensitivity and specificity, comparable to
that for quantitation, was highest using Bielschowsky silver as SoT for all SUVRs (ipsilateral, contralateral, and composite,
for both reference regions). The composite SUVR had a 100% positive predictive value (both reference regions) for the
overall pathology diagnosis. All SUVRs had a 100% negative predictive value for the Bielschowsky silver result.
Conclusion: Bielschowsky silver stain and overall pathology judgment showed the strongest associations with
imaging results.
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Despite the early description of Alzheimer’s disease (AD)
in 1906 [1], the first set of globally accepted criteria for
the clinical diagnosis of AD was only established in 1984
by the National Institute of Neurological and Communi-
cative Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association (NINCDS-ADRDA)
[2]. Prior to these criteria, a suspected clinical diagnosis
of AD could only be confirmed with certainty by the post
mortem observation of ‘senile plaques’ and neurofibrillary
tangles in the brain, much as they were described to
appear by Alois Alzheimer himself as he visualized them
with low power microscopy using Bielschowsky silver
stain [1]. While diagnosis in living patients represents a
significant advance, when applied by expert clinicians the
1984 clinical criteria are reported to have only approxi-
mately 80% positive predictive value (PPV) and 60% nega-
tive predictive value (NPV) for a pathology-confirmed
diagnosis [3]. In general, by clinical criteria, sensitivity
(proportion of true positive results) increases with more
permissive clinical criteria, and specificity (proportion of
true negative results) increases with more restrictive clin-
ical criteria. However, the opposite is true for neuropatho-
logic criteria.
Appropriately, a proposal to develop and validate new
biomarkers for AD was included in the 2011 National
Institute on Aging-Alzheimer’s Association (NIA-AA) up-
dated diagnostic recommendations [4-7]. Underpinning
the 2011 recommendations is the recognition that the
progression of AD biomarkers over time likely follows an
ordered temporal sequence, and the Aβ biomarkers (e.g.,
low brain Aβ clearance, i.e., low cerebrospinal fluid [CSF]
Aβ42; and tracer retention on amyloid positron emission
tomography [PET] imaging) are representative of up-
stream events [5].
While normally CSF flows out of the brain ventricles,
idiopathic normal pressure hydrocephalus (iNPH) may
be caused by CSF ‘backflow’ into the brain from the
ventricles [8]. Studies of various analytes have shown
that a concentration gradient exists between CSF taken
from the ventricles (higher concentration) and CSF taken
from the lumbar spine (lower concentration) [9-12]. Aβ
oligomers self-assemble into the larger Aβ species [13],
which are deposited as plaque in the brain; elevated
soluble Aβ oligomers in CSF have been associated with
AD, although the data are inconsistent and the culprit
toxic oligomer still needs to be identified [14]. With a
hypothetical leap, it may not be so surprising that
AD-like Aβ pathology frequently occurs concomitantly
with iNPH.
Clinically, patients with iNPH present with a classic triad
of symptoms: cognitive impairment, gait abnormalities,
and urinary incontinence. Untreated, iNPH is progressive
[15]. The treatment for iNPH is surgical placement of aventriculoperitoneal shunt. A small cortical biopsy from
the site of shunt placement may be obtained during the
procedure. Though iNPH itself may cause dementia, an
identifiable neurodegenerative process often underlies the
cognitive decline [16]. Concomitant AD pathology is not
uncommon [17-19], up to 68% in one series [20], and may
be associated with a poorer response to ventriculoperi-
toneal shunting [17,18]. Biopsies from iNPH patients rep-
resent a unique opportunity to study correlations between
PET amyloid imaging and pathology in living subjects.
The PET radioligand, Pittsburgh compound B (PiB),
which is a neutral analog of thioflavin T (a stain which
detects fibrillar amyloid) has been extensively studied both
in living subjects and in autopsy tissue. PiB was designed
to cross the blood-brain barrier, bind with high selectivity
and nanomolar affinity to fibrillar Aβ, and clear rapidly
from the brain [21]. Cortical [11C]PiB uptake, as measured
by PET in living subjects, correlates with fibrillar Aβ load
measured subsequently by immunohistochemical stains
for Aβ40 and Aβ42 post mortem [22-24]. Unfortunately,
the short half-life of [11C] (about 20 minutes) requires an
on-site cyclotron for its production, limiting its use to
academic medical and specialized imaging centers. Conse-
quently, several fluorinated amyloid imaging agents have
emerged to bridge this gap (F18 having a half-life of about
110 minutes): [18F]flutemetamol [25] and [18F]florbetapir
[26] (Aβ diagnostics both approved by the Food and
Drug Administration]) as well as [18F]florbetaben making
the radiopharmaceutical available for widespread com-
munity use.
[11C]PiB, [18F]florbetapir, and [18F]florbetaben have
similar fibrillar Aβ binding site affinities, and can be
used in a comparable manner to assess brain amyloid
density [27]. In this analysis, we used [18F]flutemetamol,
which differs from PiB in structure by the addition of a
single F18 atom [28].
Four clinical studies (GE067-008, -009, -010, and -011,
called Studies A, B, C, and D, here (and published separ-
ately as [20,29-31], respectively)) were undertaken in iNPH
patients requiring surgical shunt procedures or intracranial
pressure (ICP) monitoring, to determine how well cerebral
fibrillar Aβ uptake of [18F]flutemetamol as quantified by
PET imaging corresponded with immunohistochemical
(IHC) and histochemical (HC) estimates of amyloid burden
in biopsy samples taken during these procedures. Two of
the studies (one in Europe and one in the United States
[US]) were retrospective studies in which the biopsy was
followed by the PET scan. Two of the studies (one in the
Europe and one in the US) were prospective studies, in
which the order of procedures was reversed.
[18F]Flutemetamol uptake was measured quantitatively
in specific brain regions including the cortical area of (pro-
spective studies) or surrounding (retrospective studies) the
biopsy site (ipsilateral site) and the site in the contralateral
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lateral site). A composite neocortical measure of [18F]flu-
temetamol uptake was also calculated by averaging the
uptake from frontal cortex, anterior cingulate gyrus, pos-
terior cingulate gyrus/precuneus, lateral-temporal cortex,
and parietal cortex. Aβ plaque frequency was determined
and scored in biopsy specimens stained with Bielschowsky
silver stain and thioflavin S. The percentage of grey-matter
area occupied by plaque was also assessed following IHC
for the monoclonal antibody 4G8. Finally, based on all
available stains/slides, an overall pathology assessment
was rendered of the Aβ load in biopsy tissue grey matter.
These 4 pathology endpoints served as the standard of
truth (SoT) in comparisons with the [18F]flutemetamol
PET data.
In a pooled analysis of these 4 studies as previously
reported, for specific parameters, [18F]flutemetamol uptake
in ipsilateral and contralateral sites as well as the com-
posite cerebral cortical measure of [18F]flutemetamol up-
take were significantly correlated with Aβ plaque burden
[32]. This confirmed similar findings in an autopsy study
using [18F]florbetapir [33].
The standard uptake value ratio (SUVR) is a quantita-
tive measure of tracer uptake in a brain, normalized for
the mean uptake in a reference region. Pooling data
from Studies A, B, C, and D, using biopsy pathology as
the SoT and cerebellar grey matter as the quantitative
PET reference region in one set of data and pons in
another, here we set out to find (1) which pair(s) of PET
SUVR and pathology SoT endpoints matched best, (2)
whether quantitative measures of [18F]flutemetamol PET
were better for predicting the pathology outcome than
majority [18F]flutemetamol PET visual-based image read,
and (3) whether there was a better match between PET
image findings in retrospective vs. prospective studies.
Materials and methods
Patients
Patients were eligible for inclusion if they had known or
suspected iNPH, were older than 50 years of age, and were
in general health appropriate for study procedures. Pa-
tients were excluded if they were pregnant or lactating,
had known or suspected hypersensitivity/allergy to the
[18F]flutemetamol formulation, or had a contraindication
to PET or magnetic resonance imaging (MRI). For the
retrospective studies (Table 1), sufficient biopsy sample
had to be available for detection and quantification of Aβ
pathology. All 4 studies were conducted according to the
principles of the Declaration of Helsinki and approved by
local human ethics boards. Informed consent was ob-
tained from all patients and/or their designated represen-
tatives prior to study entry according to local regulations.
The number of patients and additional study characteris-
tics are summarized by study in Table 1.Procedures
[18F]Flutemetamol PET image acquisition, processing,
quantitative measures, and methodology precedents
The injected activity, PET imaging equipment used, and
details of the reconstruction of the 30-minute summed
PET image are shown by study in Table 2.
[18F]Flutemetamol was manufactured according to Good
Manufacturing Process at Cardinal Health, Beltsville, MD
for the US sites and Turku PET Center, Turku for the
Finland sites, and transported to the sites. At the PET
imaging site prior to [18F]flutemetamol injection, quality
control tests were performed including radioactivity
content and chemical purity by high-performance liquid
chromatography. The radiopharmacist ensured that the
correct activity was present in the injection syringe and
that the product was used within the validity period.
[18F]Flutemetamol (target dose, 185 MBq) was injected
over approximately 40 seconds by study staff.
The PET scan was initiated approximately 90 minutes
after injection with [18F]flutemetamol and lasted 30 minutes
(six 5-minute frames). All PET cameras in these studies
were qualified with a structured phantom prior to scanning
patients in the studies. Each site performed cycles of phan-
tom reconstruction using different filter parameters until
the spatial resolution was approximately 6.5 mm (in order
to prove approximately equal partial volume effects) [32].
The dynamic PET data was summed over the entire scan
to create a 30-minute summation image.
Within 35 days of PET imaging, patients underwent
MRI to rule out confounding conditions (e.g., vascular,
structural) and facilitate volume of interest (VOI) analysis
of [18F]flutemetamol retention. The patient’s MRI was co-
registered with the [18F]flutemetamol PET image. The bi-
opsy site on the [18F]flutemetamol image was located from
either (1) the post-biopsy MRI scan (for retrospective
studies) or (2) an MRI scan co-registered with the post-
biopsy computed tomography (CT) scan (for prospective
studies).
While the patient’s MRI was used to define the place-
ment of the VOI in the PET image for the biopsy site,
workstation functionality enabled location of an equiva-
lent region on the contralateral side. VOIs were manu-
ally drawn (1) on the tissue including the biopsy site
(prospective studies) or on the tissue surrounding the
hollow excised biopsy site (retrospective studies) and (2)
on the corresponding contralateral region. For the retro-
spective studies, measures were taken to minimize the
influence (partial volume effect) the prior surgical proced-
ure would have had on measured tracer retention, i.e.,
slightly larger VOIs were placed around the biopsy site
(and matching contralateral site). Mean VOIs are shown
in Table 3. A complete discussion of partial volume effect
is beyond the scope of this paper, but a review of the topic
can be found in [34]. Briefly, radiotracer is retained in
Table 1 Number of patients and other study characteristics, by study
Study A (Retrospective, US) Study B (Prospective, US) Study C (Retrospective, EU) Study D (Prospective, EU)
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with concomitant R prefrontal cortical
biopsy (most patients from a previous
study of the impact of AD pathology






monitoring and R frontal
cortical biopsy.
CT/MRI findings (enlarged ventricles +
obliterated cortical sulci) + at least 2
of the 3 cardinal symptoms
(abnormal gait, incontinence,
cognitive impairment) + if necessary,
positive lumbar tap test or
24-hour ICP recording.
AD = Alzheimer’s disease; CT = computed tomography; EU = Europe; ICP = intracranial pressure; iNPH = normal pressure hydrocephalus; MRI = magnetic resonance
imaging; PET = positron emission tomography; R = right; US = United States.
aIn the 2 retrospective studies (n = 22), mean (SD) time between PET and biopsy was 620.91 (384.09) days.
bIn Study A, a continuous variable regression model included percentage of area of Aβ plaque in biopsy sample tissue as measured by monoclonal antibody to
Aβ, 4G8, as dependent variable; the [18F]flutemetamol PET standard uptake value ratio (SUVR) for the contralateral volume of interest (VOI) as independent
variable; and interval from biopsy to PET scan as covariate. The result was significant for the model, and there was no apparent modulating influence of the
interval from biopsy to PET scan (p > 0.21) [20]. The results of the analysis of ipsilateral SUVR VOIs were similar. The same results were achieved using time
(in months) as a factor in a similar analysis in Study C (unpublished data).
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AD. Tracer signal from white matter may spill over any
potential cortical signal in narrow widths of cortical grey
matter. In our studies, reference VOIs were placed on 2
sites (cerebellar cortex and pons) to learn whether one ref-
erence region (REF) might be preferable to the other.Table 2 Summary of methods by study: MRI and [18F]fluteme
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Reconstruction Reconstructed by a 3-dimensional
row-action maximum likelihood algorithm.






FOV = field of view; MRI = magnetic resonance imaging; PET = positron emission tom
Note: Information in this table was extracted from the original study publications (r
documents.From studying [11C]PiB, which is structurally similar
to [18F]flutemetamol, we know that (1) regional brain
uptake of tracer is proportional to the regional level of
brain amyloid, as determined by IHC and HC [22], and
(2) symmetrically placed VOIs in the left and right frontal
cortices result in similar SUVRs [35].tamol PET image acquisition
Study C Study D





range, 169 to 184
T TRIO (Milwaukee, WI, USA) 1.5 T Philips MRI scanner
Gyroscan Intera CV Nova
Dual system (Philips Medical
Systems, Best, The Netherlands)
ce PET scanner (GE Medical Systems,
e, WI, USA) in 3D modes with a
axial FOV obtained in a single FOV
ECAT EXACT HR + scanner
(Siemens-CTI, Knoxville,
TN, USA)
cted to 35 transaxial images of 128 x 128
a back-projection algorithm using
urer-provided software correcting for
n, scatter, and dead time. Resolution was
ately 6 mm at full width at half maximum.
Not stated. Not stated.
ography.
efer to text) and supplemented with data from the clinical trial submission
Table 3 Mean volumes of interest for retrospective and prospective studies [32]
Retrospective studies (Studies A and C) Prospective studies (Studies B and D)
Mean VOI (SD) Minimum-maximum Mean VOI (SD) Minimum-maximum
Ipsilateral 1.17 mL (0.23) 0.61 – 1.58 0.55 mL (0.07) 0.37 – 0.70
Contralateral 0.91 mL (0.25) 0.52 – 1.33 0.54 mL (0.06) 0.42 – 0.71
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SUVVOI/SUVREF, with SUV being the integrated activ-
ity over a given time period per unit of injected dose
and body weight. The reference regions, cerebellar cortex
and pons, were not expected to have any fibrillar Aβ
plaque burden. Previous work has shown that the SUVR
range of [18F]flutemetamol referenced to cerebellum in
normal subjects is between 1.1 and 1.5 [36]. It should be
noted, however, that in addition to mature (dense, cored)
neuritic plaques, and to a much lesser degree diffuse Aβ
plaques, [18F]flutemetamol is retained by vascular amyloid
deposits [22]. The results from the original studies showed
that 3/43 patients examined for vascular amyloid in the
pooled dataset were positively identified by the pathologist
(1 with an overall pathology diagnosis of normal).
A mean composite cortical VOI was calculated as the
mean of several anatomic regions typically associated
with significant Aβ plaque burden in AD (frontal cortex,
anterior cingulate gyrus, posterior cingulate gyrus/precu-
neus, lateral-temporal cortex, and parietal cortex). Neo-
cortex is associated with Thal Phase 1 of Aβ deposition
in AD, and cingulate is associated with Thal Phase 2
(out of 5 phases) [37]. Thal Phases 1 and 2 correspond
to the designation “A1” according to the “ABC” system
set forth in the NIA-AA guidelines for the neuropatho-
logic assessment of AD [38]. Similar composite measure-
ments have been previously described for [11C]PiB [39],
[18F]flutemetamol [36], and [18F]florbetaben [40]. Since
the five brain regions vary considerably in size, and the
mean was not corrected for VOI size, the SUVR of the
composite VOI reflects the level of uptake as if all 5
regions were of equal importance and not the overall
uptake level in the composite VOI. Composite cortical
SUVR has resulted in a value (i.e., overall estimate) of
the fibrillar Aβ burden in the brain as a whole similar to
that for the biopsy VOI [41] and is similar to a global
PiB retention summary from 6 cortical regions of inter-
est as justified in [42].
[18F]Flutemetamol PET blinded image evaluation
Anonymized [18F]flutemetamol PET data were transferred
to the GE Healthcare Image Review Center in Oslo,
Norway, and reviewed according to the studies’ image re-
view charters and in accordance with United States Food
and Drug Administration Guidance to Industry [http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRe
gulatoryInformation/Guidances/UCM268555.pdf]. Imageswere loaded onto Xeleris workstations (GE Medical Sys-
tems, Milwaukee, WI) and reviewed using its Volumetrix
application.
Visual interpretation of images by readers blinded to
subject clinical and pathological information except for
iNPH status (blinded image examination [BIE]) was
performed by 3 trained, experienced raters (nuclear medi-
cine physicians) in each study, in an individually random-
ized order of image presentation. Inter-rater agreement
has previously been shown to be strong [32]. All readers
assessed the grey matter tracer patterns in the same
protocol-specified regions, in the same protocol-specified
order.
Biopsy
Biopsy tissue was taken with biopsy forceps or a 14-
gauge biopsy needle. The biopsy sample in Study A was
approximately 5 mm3 and in the other 3 studies was
approximately 14 mm3. In Study A, the biopsy was from
the right prefrontal cortex; in Studies C and D, right pre-
frontal cortex, mid-pupillary line in front of the coronal
suture was specified. In accordance with neurosurgical
procedures approved by the institutional review board for
the Johns Hopkins site, parietal cortex was biopsied in
Study B.
Immunohistochemistry (4G8) and histochemistry (thioflavin
S and Bielschowsky silver) methodology and measures
The biopsy tissue was fixed in 10% neutral buffered
formalin and embedded in paraffin. If the sample size
allowed, up to 50 serial sections were cut at a 5-μm
thickness (6 μm in Study A) and numbered sequentially.
Wherever possible, 3 sections separated by 100 μm (e.g.,
Slides 3, 23, and 43) from each biopsy were used for
each of 3 staining techniques: 4G8 IHC, Bielschowsky
silver, and thioflavin S. 4G8 IHC was standardized using
the methodology of Study A as a model, and performed
for Studies B, C, and D at Covance Laboratories Ltd
(Harrogate, North Yorkshire, UK) as previously detailed
[32]. Formic acid pre-treatment was used. Five measures
(Aβ percentage area or plaque score, described below)
were taken from each slide, and a mean was determined
for each specimen.
Automated histometric measurement of the percent-
age area of Aβ in grey matter in 4G8 stained sections
was performed. Except for 4G8 sections from only 7
subjects for whom Aβ percentage area was measured at
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(Study A [20]), 4G8 sections were imaged using whole
slide scanning (Aperio XT) with a pre-developed and
validated macro (MATLAB) used to threshold intensity,
size, and morphometry after color deconvolution to
remove the hematoxylin staining channel. The 4G8 anti-
body dilution for the 7 samples from Study A was higher
(1:500) than for the remaining 40 available 4G8 samples
(1:100). Three of these 7 samples were completely 4G8
negative (0.00% 4G8); 4G8 percentage area was 0.07%,
1.52%, 2.05%, and 2.75%, respectively, in the remaining 4
samples. In Studies B, C, and D a total of 5 out of 40
samples were completely 4G8 negative, and 4G8 percent-
age area in the remaining 35 samples ranged from 0.01%
to 13.41%.
To dichotomise the 4G8 data (normal/abnormal) we
used a threshold of 2.5% (receiver-operator characteristics
analysis from multiple cortical samples taken in an
autopsy study cohort of 68 subjects, data not shown). In
11/47 4G8 samples, the cut-off definition did not match
the overall pathology judgment (8 samples with 4G8 posi-
tivity ≤2.5% had an overall pathology judgment of abnor-
mal, and 3 samples with 4G8 positivity >2.5% had an
overall pathology judgment of normal).
In Bielschowsky silver and thioflavin S stained sections,
plaques were counted and scored using the following modi-
fied Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) 4-point scale [43]: 0 = no plaques, 1 =
sparse plaques (1 to 5), 2 =moderate plaques (6 to 19),
and 3 = frequent plaques (20+). For Study A, Bielschowsky
silver and thioflavin S plaque counts were not assessed
using the same scale as in the other studies, and were
therefore not included in the pooled data set. For one
subject in Study C, the thioflavin S result (average of 3
sections with plaque scores of 0, 1, and 2, respectively)
was changed from abnormal to normal after the re-
sults of the study were known. This was justified be-
cause, according to the published methods for Study C,
only a plaque score of 2 (moderate) or 3 (frequent) for
thioflavin S was considered abnormal [30], and justified
also according to the standardized analysis definitions
for this study. All other outcomes for this subject
were abnormal.
All staining methods were pre-validated and optimized
prior to study samples being stained. It is acknowledged
that Bielschowsky silver stain is not readily scaled up
and was performed in small batches along-side control
sections. The neuropathologists assessing the sections
were at liberty to request re-stains, and comments on
the quality of the sections actually assessed were col-
lected. Good, Satisfactory and Poor meant that sections
were assessable with varying degrees of ease while the
option to record the sections as “Unassessable” was
also available.The physician evaluating the 4G8 slides for Study A
was blinded to case identity. The independent neuropath-
ologist at the contract research organization evaluating all
other slides was blinded to clinical and imaging data; 4G8
slides for histometric analysis were scanned at a separate
location, and the same slides were then shipped and used
in the neuropathologic assessment.
Statistical analysis
All 24 possible combinations (pairs) of the following 4
pathology SoTs and 6 image endpoints were studied:
Pathology data (SoT)
(a) Plaque as a percentage of area IHC-stained with
4G8 antibody
(b) Bielschowsky silver plaque score (normal/abnormal)
(c) Thioflavin S plaque score (normal/abnormal)
(d) Overall pathology (normal/abnormal)
Normal and abnormal are defined below.
Imaging data (SUVR type)
Cerebellum as reference
(i) SUVR for the ipsilateral VOI
(ii) SUVR for the matching contralateral VOI
(iii)SUVR for the composite VOI
Pons as reference
(iv) SUVR for the ipsilateral VOI
(v) SUVR for the matching contralateral VOI
(vi) SUVR for the composite VOI
Additionally, the results of the BIE were an endpoint.
There were only SUVR readings and a BIE reading for
1 patient included in the analysis (no pathology IHC or
HC was available for this patient).
An explanation of the sequence and logic of statistical
analysis processes is presented at the end of this statistical
methodology section, after all the terms have been defined.
Objective 1: The first objective of the statistical ana-
lysis was to determine which pair of SUVR/pathology
endpoints matched best.
Analysis: For each of the 4 pathology SoTs, the result was
dichotomized as normal or abnormal. For 4G8 IHC (a), if
the area was ≤2.5% it was classified as normal; otherwise, it
was abnormal. For Bielschowsky silver stain (b) and thiofla-
vin S (c), the normal/abnormal plaque score threshold was
the midpoint between sparse and moderate (i.e., ≤1.5 was
defined as normal). In addition, an overall pathology SoT
(d) consisted of the pathologist’s overall impression (normal
or abnormal) based on all slides prepared. The overall
Table 4 Scheme for classifying biopsy results
[18F]flutemetamol
PET result
Aβ Pathology standard of truth
Abnormal Normal
Abnormal True positive (TP) False positive (FP)
Normal False negative (FN) True negative (TN)
Table 5 Definitions for diagnostic efficacy of
[18F]flutemetamol PET
Metric Definition
Sensitivitya TP/TP + FN
Specificitya TN/TN + FP
Accuracyb TP + TN/TP + FN + TN + FP
Positive predicative value (PPV)a TP/TP + FP
Negative predictive value (NPV)a TN/TN + FN
aThe highest possible value of the result is 1. This result generally does not
depend on disease prevalence.
bThe highest possible accuracy is 1. Accuracy is a function of disease prevalence
in the population being tested.
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independent expert neuropathologist (blinded to clinical in-
formation) to allow for discrepant results from the 3 stain-
ing methods (if any) resulting in the final classification of
each case as normal or abnormal.
Based on each pathology SoT, receiver-operator charac-
teristic (ROC) analyses (defined below) were performed,
in which the discriminative ability of each SUVR type
(i through vi) was tested against each pathology SoT
(a through d). For each of these 24 ROC analyses, the
area under the curve (AUC) value was determined. In
addition, for each ROC curve, the optimal threshold
for each SUVR score was determined by the Youden
index [44] using MedCalc software (Ostend, Belgium).
After obtaining the optimal threshold for each ROC
analysis, the sensitivity, specificity, PPV, NPV, and ac-
curacy of each SUVR method for prediction of each
SoT were calculated.
Result: The best matched pair (SUVR type and SoT)
would be the one which has the highest AUC value in
the ROC analysis, the largest sum of sensitivity and
specificity [45], or the largest Youden index.
Objective 2: The second objective of the statistical
analysis was to determine whether SUVR was a better
measure for predicting SoT outcome than the majority
BIE result (i.e., at least 2 of 3 readers).
Analysis: Based on each pathology SoT, we compared
the sensitivity and specificity of majority BIE read to the
sensitivity and specificity of SUVR with the McNemar
test (used to compare paired proportions).
Result: The results were expressed as point estimates
of the sensitivity and specificity values for both BIE and
SUVR, their 95% confidence intervals (CIs), and p-values
for the comparisons.
Objective 3: The third objective of the statistical ana-
lysis was to determine whether there was a better match
between PET imaging findings and pathology findings in
retrospective or prospective studies.
Analysis: For each pathology SoT, we determined
whether the pairing of PET SUVR type and SoT with
the largest sum of sensitivity and specificity was for pro-
spective or retrospective studies. We also determined,
for each pathology SoT and PET SUVR type, which
study cohort (prospective or retrospective) had the larger
sum of sensitivity and specificity.
Result: The results were expressed as point estimates
of the sum of the sensitivity and specificity values and
their 95% CIs.
Definitions and explanation of terms
The scheme for classifying biopsy results is shown in
Table 4.
The definitions for diagnostic efficacy are shown in
Table 5 where TP, FN, FP, TN are numbers of patients.A ROC curve is the graph where the y axis represents
sensitivity and the x axis represents 1 minus specificity.
The ROC AUC is a measure of test performance with a
ROC AUC of 1 indicating a perfect test.
The sum of sensitivity and specificity indicates whether
a diagnostic test will result in a revision of the pre-test
probability of disease [45]. The highest possible sum of
sensitivity and specificity is 2.
The Youden index is the sum of sensitivity and spe-
cificity minus 1; a perfect test would have a Youden
index of 1.
SUVR thresholds
Using all of the available SUVR values for each combin-
ation of the 6 SUVR types, an estimate was made of the
SUVR value that would maximize the value of the Youden
index. These maximal Youden values and their optimal
SUVR values are shown in Table 6. These SUVR values
that maximized the Youden index values were then used
to calculate ROC AUCs (also shown in Table 6).
Sequence and logic of statistical analysis process
Here is the sequence and logic for the statistical analysis
process. There are 24 combinations of SUVR type (6)
and pathology SoT (4). For each of these 24 combina-
tions there are approximately 49 sets of SUVR values
(quantitative—continuous scale) and pathology SoT value
(always dichotomized—normal/abnormal as described
above). For each of 24 combinations, an ROC curve is
generated using the “population” of data (SUVR and SoT
values). For any 1 SUVR value, a point on the ROC is
determined, since both sensitivity and specificity are deter-
mined by use of that SUVR value as a cut-off (SUVR
values below that cut-off are termed normal, and SUVR
Table 6 ROC AUC, Youden index, and Optimal SUVR thresholds by SUVR type and pathology SoT for all 4 studies
combined
Pathology standard of truth
SUVR type
SUVR brain region REF ROC AUC Maximal Youden index SUVR cut-off criterion
4G8
Ipsilateral Cerebellum 0.8544 0.6216 >1.25
Contralateral Cerebellum 0.8529 0.6757 >1.24
Composite Cerebellum 0.7508 0.5315 >1.79
Ipsilateral Pons 0.7763 0.5000 >0.42
Contralateral Pons 0.7853 0.5468 >0.44
Composite Pons 0.7583 0.5205 >0.45
Bielschowsky
Ipsilateral Cerebellum 0.9769 0.8889 >1.31
Contralateral Cerebellum 0.9769 0.8889 >1.31
Composite Cerebellum 0.9815 0.9259 >1.38
Ipsilateral Pons 0.9699 0.8214 >0.46
Contralateral Pons 0.9815 0.9286 >0.48
Composite Pons 0.9792 0.8571 >0.48
Thioflavin S
Ipsilateral Cerebellum 0.9288 0.7465 >1.62
Contralateral Cerebellum 0.9253 0.7951 >1.31
Composite Cerebellum 0.9462 0.8438 >1.34
Ipsilateral Pons 0.8767 0.6465 >0.46
Contralateral Pons 0.9132 0.7980 >0.48
Composite Pons 0.9236 0.7374 >0.5
Overall pathology
Ipsilateral Cerebellum 0.9916 0.9286 >1.5
Contralateral Cerebellum 0.9979 0.9706 >1.31
Composite Cerebellum 1.0000 1.0000 >1.46
Ipsilateral Pons 0.9433 0.7857 >0.472
Contralateral Pons 0.9842 0.8857 >0.479
Composite Pons 0.9947 0.9286 >0.53
AUC = area under the curve; REF = brain reference region; ROC = receiver-operator curve; SUVR = standard uptake value ratio; SoT = standard of truth; VOI = volume
of interest.
Note: SUVR cut-off criterion is the SUVR value that maximizes the value of the Youden index. The SUVR cut-off value is the SUVR value above which lies a reading
of abnormal and below or equal to which is a reading of normal.
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value is already labeled as normal or abnormal by the
pathology cut-off values).
Considering all values on the ROC curve, 1 value on
the ROC curve will be a maximum value for the Youden
index, which is just (sensitivity + specificity -1). If the
Youden index is maximized at a point on the ROC
curve, then clearly the sum of sensitivity and specificity
will also be maximal at the same point on the ROC
curve. We recorded at what SUVR cut-off value the
maximal Youden index (and thus the maximal sum of
sensitivity and specificity) was found. These are the so-called “optimal SUVR thresholds” (Table 6 in Results). All
subsequent diagnostic efficacy parameters were computed
using this optimal SUVR threshold. Thus, in Table 7, the
“sum of sensitivity and specificity values” are actually the
“maximal sum of sensitivity and specificity values” for
each combination of SUVR type and pathology SoT. The
sensitivity and specificity values given for each combin-
ation are those at the SUVR threshold that maximized the
sum of sensitivity and specificity for that combination.
The number and percentage of TP, FN, TN, and FP
values (refer to Table 4) given in Table 8 (and the values
computed from them (accuracy, PPV, and NPV) are all
Table 7 Sensitivity and specificity and their exact 95% CIs for each SUVR type/pathology SoT combination for all 4 studies combined
Cerebellum REF Pons REF
Pathology SoT Ipsilateral Contralateral Composite Ipsilateral Contralateral Composite
4G8
Sensitivity (95% CI) 1.0000 (0.6637, 1.0000) 1.0000 (0.6637, 1.0000) 0.6667 (0.2993, 0.9251) 1.0000 (0.6637, 1.0000) 0.8889 (0.5175, 0.9972) 0.8889 (0.5175, 0.9972)
Specificity (95% CI) 0.6216 (0.4476, 0.7754) 0.6757 (0.5021, 0.8199) 0.8649 (0.7123, 0.9546) 0.5000 (0.3338, 0.6662) 0.6579 (0.4865, 0.8037) 0.6316 (0.4599, 0.7819)
Maximal sum (sensitivity + specificity) 1.6216 1.6757 1.5316 1.5000 1.5468 1.5205
Bielschowsky
Sensitivity (95% CI) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000)
Specificity (95% CI) 0.8889 (0.7084, 0.9765) 0.8889 (0.7084, 0.9765) 0.9259 (0.7571, 0.9909) 0.8214 (0.6311, 0.9394) 0.9286 (0.7650, 0.9912) 0.8571 (0.6733, 0.9597)
Maximal sum (sensitivity + specificity) 1.8889 1.8889 1.9259 1.8214 1.9286 1.8571
Thioflavin S
Sensitivity (95% CI) 0.7778 (0.3999, 0.9719) 0.8889 (0.5175, 0.9972) 1.0000 (0.6637, 1.0000) 0.8889 (0.5175, 0.9972) 0.8889 (0.5175, 0.9972) 0.8889 (0.5175, 0.9972)
Specificity (95% CI) 0.9688 (0.8378, 0.9992) 0.9063 (0.7498, 0.9802) 0.8438 (0.6721, 0.9472) 0.7576 (0.5774, 0.8891) 0.9091 (0.7567, 0.9808) 0.8485 (0.6810, 0.9489)
Maximal sum (sensitivity + specificity) 1.7466 1.7952 1.8438 1.6465 1.7980 1.7374
Overall pathology
Sensitivity (95% CI) 0.9286 (0.6613, 0.9982) 1.0000 (0.7684, 1.0000) 1.0000 (0.7684, 1.0000) 0.9286 (0.6613, 0.9982) 1.0000 (0.7684, 1.0000) 0.9286 (0.6613, 0.9982)
Specificity (95% CI) 1.0000 (0.8972, 1.0000) 0.9706 (0.8467, 0.9993) 1.0000 (0.8972, 1.0000) 0.8571 (0.6974, 0.9519) 0.8857 (0.7326, 0.9680) 1.0000 (0.9000, 1.0000)
Maximal sum (sensitivity + specificity) 1.9286 1.9706 2.0000 1.7857 1.8857 1.9286





















Table 8 Accuracy of [18F]flutemetamol quantitative diagnosis and positive and negative predictive values by Aβ
pathology SoT in the 4 studies combined
Pathology standard of truth
SUVR type SUVR/SoT, N (%) N (%)
Brain SUVR region REF TN n (%) FN n (%) FP n (%) TP n (%) Total Accuracya PPVb NPVc
4G8% area
Ipsi C 23 (62) 0 (0) 14 (38) 9 (100) 46 69.57 39.13 100.00
Contra C 25 (68) 0 (0) 12 (32) 9 (100) 46 73.91 42.86 100.00
Comp C 32 (86) 3 (33) 5 (14) 6 (67) 46 82.61 54.55 91.43
Ipsi P 19 (50) 0 (0) 19 (50) 9 (100) 47 59.57 32.14 100.00
Contra P 25 (66) 1 (11) 13 (34) 8 (89) 47 70.21 38.10 96.15
Comp P 24 (63) 1 (11) 14 (37) 8 (89) 47 68.09 36.36 96.00
Bielschowsky silver plaque score
Ipsi C 24 (89) 0 (0) 3 (11) 8 (100) 35 91.43 72.73 100.00
Contra C 24 (89) 0 (0) 3 (11) 8 (100) 35 91.43 72.73 100.00
Comp C 25 (93) 0 (0) 2 (7) 8 (100) 35 94.29 80.00 100.00
Ipsi P 23 (82) 0 (0) 5 (18) 8 (100) 36 86.11 61.54 100.00
Contra P 26 (93) 0 (0) 2 (7) 8 (100) 36 94.44 80.00 100.00
Comp P 24 (86) 0 (0) 4 (14) 8 (100) 36 88.89 66.67 100.00
Thioflavin S plaque score
Ipsi C 31 (97) 2 (22) 1 (3) 7 (78) 41 92.68 87.50 93.94
Contra C 29 (91) 1 (11) 3 (9) 8 (89) 41 90.24 72.73 96.67
Comp C 27 (84) 0 (0) 5 (16) 9 (100) 41 87.80 64.29 100.00
Ipsi P 25 (76) 1 (11) 8 (24) 8 (89) 42 78.57 50.00 96.15
Contra P 30 (91) 1 (11) 3 (9) 8 (89) 42 90.48 72.73 96.77
Comp P 28 (85) 1 (11) 5 (15) 8 (89) 42 85.71 61.54 96.55
Overall pathology
Ipsi C 34 (100) 1 (7) 0 (0) 13 (93) 48 97.92 100.00 97.14
Contra C 33 (97) 0 (0) 1 (3) 14 (100) 48 97.92 93.33 100.00
Comp C 34 (100) 0 (0) 0 (0) 14 (100) 48 100.00 100.00 100.00
Ipsi P 30 (86) 1 (7) 5 (14) 13 (93) 49 87.76 72.22 96.77
Contra P 31 (89) 0 (0) 4 (11) 14 (100) 49 91.84 77.78 100.00
Comp P 35 (100) 1 (7) 0 (0) 13 (93) 49 97.96 100.00 97.22
C = cerebellum; Comp = composite; Contra = contralateral; FN = false negatives; FP = false positives; Ipsi = ipsilateral; N = number of patients; NPV = negative
predictive value; P = pons; PPV = positive predictive value; REF = PET imaging brain reference region; ROC = receiver-operator curve; SoT = standard of truth;
TN = true negatives; TP = true positives; SUVR = standard uptake value ratio.
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threshold, that is, the SUVR threshold that maximized
the Youden index/sum of sensitivity and specificity for
that combination of SUVR type and pathology SoT.
It is not shocking that the larger ROC AUCs generally
occur with larger Youden indices, since a large Youden
index means a large sum of sensitivity and specificity,
and the maximal ROC AUC is observed when both
sensitivity and specificity are 1.0. The Sigma Plot instruc-
tions for ROC curve analysis state “An important measure
of the accuracy of the clinical test is the area under the
ROC curve. If this area is equal to 1.0 then the ROC curve
consists of two straight lines, one vertical from 0,0 to 0,1and the next horizontal from 0,1 to 1,1. This test is 100%
accurate because both the sensitivity and specificity are
1.0 so there are no false positives and no false negatives.”
Comparing diagnostic efficacy values using BIE and
pathology SoT is essentially exactly the same as using
dichotomized SUVR values. In both cases, the imaging
judgment has been dichotomized into normal or abnor-
mal, either from using a cut-off value for SUVR or an
immediate visual judgment for BIE.
Results
Unless stated otherwise, results shown are for Studies A,
B, C, and D combined. Representative photomicrographs
Leinonen et al. Acta Neuropathologica Communications 2014, 2:46 Page 11 of 22
http://www.actaneurocomms.org/content/2/1/46of Bielschowsky silver stain and 4G8 stain are displayed
in Figure 1 alongside examples of abnormal and normal
PET images.
SUVR type/pathology SoT pairs with highest ROC AUC
and largest Youden index
Including all data from the 4 pooled studies com-
bined, for 3 of the 4 pathology SoTs, the SUVR type
with the largest ROC AUC was the composite SUVR
referenced to the cerebellum (composite-cerebellum)
(overall pathology [AUC = 1.0000], Bielschowsky silver
[AUC= 0.9815], and thioflavin S [AUC= 0.9462]) (Table 6).
For Bielschowsky silver, the ROC AUC was as large for
contralateral-cerebellum as for composite-cerebellum. For
the fourth pathology SoT, the SUVR type with the largest
ROC AUC completing the pair was ipsilateral-cerebellum
(4G8 [AUC= 0.8544]).
Considering all SUVR type/pathology SoT pairs, the
composite-cerebellum/overall pathology pair had the
largest ROC AUC (1.000). ROC AUCs for composite-
cerebellum/and contralateral-pons/Bielschowsky silver were
nearly as large (both 0.9815) (Figure 2).
The combination of SUVR type/pathology SoT with the
largest Youden index (1.0000) was composite-cerebellum/
overall pathology (Table 6). For the other 3 pathology SoTs,
the SUVR types with the largest Youden index in descend-
ing order were as follows: contralateral-pons/BielschowskyAmyloid IHC
Bielschowsky
a Abnormal Normal b
Par
Fro
Figure 1 Examples of abnormal and normal [18F]flutemetamol positro
resonance (MR) or computed tomography (CT) imaging and histopath
histopathology (Study D). Amyloid plaques were determined in biopsy sam
identified in serial sections using a modified Bielschowsky silver stain. Pane
after biopsy (Studies A and C) or prospectively before biopsy (Studies B and
histopathology was correlated to standard uptake value ratio (SUVR) measu
site of biopsy.silver (0.9286), composite-cerebellum/thioflavin S (0.8438),
and contralateral-cerebellum/4G8 (0.6757).
The largest Youden index for each pathology SoT was
almost always found in the SUVR type/SoT pair with
the largest ROC AUC. The exception was for 4G8, with
the largest Youden index for the combination with ROC
AUC of 0.8529, not the combination with the ROC AUC
of 0.8544 (Table 6).
All of the SUVR cut-off criteria using cerebellum as
the reference region were greater than 1. None of the
SUVR cut-off criteria using pons as the reference region
were greater than 1.
SUVR type/pathology SoT pairs with largest sum of
sensitivity and specificity (4 studies combined) (Table 7)
The SUVR type with the highest sum of sensitivity and
specificity for each SoT in order of descending value was
composite-cerebellum/overall pathology (2.000), contralat-
eral-pons/Bielschowsky silver (1.9286), composite-cerebel-
lum/thioflavin S (1.8438), and contralateral-cerebellum/
4G8 (1.6757).
For 4G8, sensitivity was good, greater than 0.8889 for all
SUVR types (and similar to that for the other pathology
SoTs), but specificity was poorer (range, 0.5000 to 0.8649).
Sensitivity, specificity, accuracy, PPV, and NPV values












n emission tomography (PET) and corresponding magnetic
ology. Panel a) [18F]Flutemetamol PET imaging correlates with
ples by 4G8 imunohistochemistry (IHC). Neuritic plaques were
l b) [18F]Flutemetamol PET images were obtained either retrospectively
D). Small cortical biopsies were taken during shunt placement and
res in volumes of interest (VOIs) either ipsilateral or contralateral to the
a   ROC - 4G8 immunohistochemistry as standard of truth b ROC - Bielschowsky silver as standard of truth
c   ROC - Thioflavin S as standard of truth d ROC - Overall pathology judgment as standard of truth
Figure 2 Receiver-operator curves by pathology standard of truth for each SUVR type: a) 4G8, b) Bielschowsky silver stain, c) Thioflavin S,
and d) Overall Pathology. The composite-cerebellum/overall pathology pair had the largest ROC AUC (1.000). ROC AUCs for composite-cerebellum/
and contralateral-pons/Bielschowsky silver were nearly as large (both 0.9815).
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sum of sensitivity and specificity (quantitative SUVR vs. BIE)
(Table 9)
When using Bielschowsky silver as the SoT, the sum
of sensitivity and specificity was greater for BIE than for
the quantitative SUVR for all of the SUVR types (6/6)
(range of differences across SUVR types, 0.0357 [3.57%]
to 0.1429 [14.29%]).
When using 4G8 or thioflavin S as the SoT, the sum of
sensitivity and specificity was greater for quantitative
SUVR than for the BIE for the majority of the SUVR
types (6/6 for 4G8, 5/6 for thioflavin S) (Table 9). The
only statistically significant differences were that speci-
ficity for BIE majority read was higher than specificity
for the quantitative SUVR for the following: for 4G8,
ipsilateral-cerebellum and all SUVR types-pons; and for
thioflavin S, ipsilateral-pons.
Using overall pathology as the SoT, the sum of sensi-
tivity and specificity for BIE and quantitative SUVR were
tied (BIE was higher for 2 of 6 SUVR types, quantitativeSUVR was higher for 2 of 6 SUVR types, and BIE and
quantitative SUVR were tied for 2 of 6 SUVR types).
SUVR type/pathology SoT pairs with largest sum of
sensitivity and specificity (retrospective vs. prospective
studies) (Table 10)
For the pathology SoTs Bielschowsky silver, thioflavin
S, and 4G8, in the majority of SUVR type/pathology SoT
combinations (5/6, 4/6, and 4/6, respectively), the sum
of sensitivity and specificity was larger for prospective
rather than retrospective studies (Table 10).
For the overall pathology SoT, SUVR type/pathology
SoT the sum of sensitivity and specificity was tied in 1
of 6 combination pairs, larger in retrospective studies in
3 of 6 pairs, and larger in prospective studies in 2 of 6
pairs.
For retrospective studies, the SUVR types with the
highest sum of sensitivity and specificity by pathology







Figure 3 Diagnostic efficacy by SUVR type (a – c using
cerebellum as reference region, d – f using pons as reference
region) for each pathology standard of truth (within each
group from left to right: 4G8 [blue], Bielschowsky Silver [rust],
Thioflavin S [green], and Overall Pathology [purple]). Horizontal
axis: Groups of bars from left to right represent Sensitivity, Specificity,
Accuracy, PPV, and NPV. Vertical axis: Percentage (maximum 100%).
Error bars represent 95% confidence intervals.
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silver, composite-cerebellum (1.9375); for thioflavin S,
composite-cerebellum (1.8947); and for 4G8, contralat-
eral-cerebellum (1.75).
For prospective studies, the SUVR types with the high-
est sum of sensitivity and specificity by pathology SoT in
descending order were as follows: for overall pathology,
contralateral-cerebellum and composite-cerebellum (both
2.00); for Bielschowsky silver, contralateral-pons (2.00);
for thioflavin S, contralateral-pons (1.9231); and for
4G8, ipsilateral-cerebellum and contralateral-pons (both
1.6471).
Accuracy of quantitative SUVR diagnosis, positive and
negative predictive values
In addition to sensitivity and specificity, accuracy, PPV,
and NPV were calculated (Table 8). The numbers and
proportions of FN and FP results were lowest in the
overall pathology SoT. For each of the 3 stains (IHC and
HC), the proportions of patients with FP are substan-
tially greater than the proportions of patients with FN.
SUVR types that had a 100% PPV were only found in
the overall pathology SoT (ipsilateral-cerebellum, compos-
ite-cerebellum, and composite-pons). All SUVR types had
a 100% NPV for the Bielschowsky silver SoT. Composite-
cerebellum had 100% accuracy for 3 of the 4 SoTs (all but
4G8). The 4G8 pathology SoT had the lowest PPV and
accuracy.
Discussion
Given that the SUVR of the composite VOI does not
reflect the overall uptake level in the composite VOI
(i.e., the mean value is not corrected for VOI size
and all regions are treated as though they were of
equal importance) it is perhaps unexpected that the
composite measure for SUVR referenced to the cere-
bellum for all 4 studies combined was a better match
with biopsy pathology findings for 2 pathology SoTs
(overall pathology and Bielschowsky silver) than was
the SUVR (any combination) from the biopsy region
itself or its contralateral homolog. However, when the
retrospective and prospective studies were analyzed separ-
ately, for retrospective studies, composite-cerebellum was
generally the best match for the SoTs, while for the pro-
spective studies, contralateral-pons was generally the best
Table 9 Sensitivity, specificity, and exact 95% CIs for each image reading method (quantitative vs. majority BIE) by pathology SoT for all 4 studies combined
Cerebellum REF Pons REF
Pathology SoT Ipsilateral Contralateral Composite Ipsilateral Contralateral Composite
4G8
Quantitative (SUVR)
Sensitivity (95% CI) 1.0000 (0.6637, 1.0000) 1.0000 (0.6637, 1.0000) 0.6667 (0.2993, 0.9251) 1.0000 (0.6637, 1.0000) 0.8889 (0.5175, 0.9972) 0.8889 (0.5175, 0.9972)
Specificity (95% CI) 0.6216* (0.4476, 0.7754) 0.6757 (0.5021, 0.8199) 0.8649 (0.7123, 0.9546) 0.5000* (0.3338, 0.6662) 0.6579* (0.4865, 0.8037) 0.6316 a (0.4599, 0.7819)
Sum (sensitivity + specificity) 1.6216 1.6757 1.5316 1.5000 1.5468 1.5205
BIE
Sensitivity (95% CI) 0.6667 (0.2993, 0.9251) 0.6667 (0.2993, 0.9251) 0.6667 (0.2993, 0.9251) 0.6667 (0.2993, 0.9251) 0.6667 (0.2993, 0.9251) 0.6667 (0.2993, 0.9251)
Specificity (95% CI) 0.8108* (0.6484, 0.9204) 0.8108 (0.6484, 0.9204) 0.8108 (0.6484, 0.9204) 0.8158* (0.6567, 0.9226) 0.8158* (0.6567, 0.9226) 0.8158* (0.6567, 0.9226)
Sum (sensitivity + specificity) 1.4775 1.4825 1.4775 1.4825 1.4825 1.4825
Bielschowsky
Quantitative (SUVR)
Sensitivity (95% CI) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000)
Specificity (95% CI) 0.8889 (0.7084, 0.9765) 0.8889 (0.7084, 0.9765) 0.9259 (0.7571, 0.9909) 0.8214 (6311, 9394) 0.9286 (0.7650, 0.9912) 0.8571 (0.6733, 0.9597)
Sum (sensitivity + specificity) 1.8889 1.8889 1.9259 1.8214 1.9286 1.8571
BIE
Sensitivity (95% CI) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000)
Specificity (95% CI) 0.9630 (0.8103, 0.9991) 0.9630 (0.8103, 0.9991) 0.9630 (0.8103, 0.9991) 0.9643 (0.9165, 0.9991) 0.9643 (0.8165, 0.9991) 0.9643 (0.8165, 0.9991)
Sum (sensitivity + specificity) 1.9630 1.9630 1.9630 1.9643 1.9643 1.9643
Thioflavin S
Quantitative (SUVR)
Sensitivity (95% CI) 0.7778 (0.3999, 0.9719) 0.8889 (0.5175, 0.9972) 1.0000 (0.6637, 1.0000) 0.8889 (0.5175, 0.9972) 0.8889 (0.5175, 0.9972) 0.8889 (0.5175, 0.9972)
Specificity (95% CI) 0.9688 (0.8378, 0.9992) 0.9063 (0.7498, 0.9802) 0.8438 (0.6721, 0.9472) 0.7576* (0.5774, 0.8891) 0.9091 (0.7567, 0.9808) 0.8485 (0.6810, 0.9489)
Sum (sensitivity + specificity) 1.7466 1.7952 1.8438 1.6465 1.7980 1.7374
BIE
Sensitivity (95% CI) 0.7778 (0.3999, 0.9719) 0.7778 (0.3999, 0.9719) 0.7778 (0.3999, 0.9719) 0.7778 (0.3999, 0.9719) 0.7778 (0.3999, 0.9719) 0.7778 (0.3999, 0.9719)
Specificity (95% CI) 0.9375 (0.7919, 0.9923) 0.9375 (0.7919, 0.9923) 0.9375 (0.7919, 0.9923) 0.9394* (0.7977, 0.9926) 0.9394 (0.7977, 0.9926) 0.9394 (0.7977, 0.9926)

























Sensitivity (95% CI) 0.9286 (0.6613, 0.9982) 1.0000 (0.7684, 1.0000) 1.0000 (0.7684, 1.0000) 0.9286 (0.6613, 0.9982) 1.0000 (0.7684, 1.0000) 0.9286 (0.6613, 0.9982)
Specificity (95% CI) 1.0000 (0.8972, 0.1.000) 0.9706 (0.8467, 0.9993) 1.0000 (0.8972, 1.0000) 0.8571 (0.6974, 0.9519) 0.8857 (0.7326, 0.9680) 1.0000 (0.9000, 1.0000)
Sum (sensitivity + specificity) 1.9286 1.9706 2.000 1.7857 1.8857 1.9286
BIE
Sensitivity (95% CI) 0.9286 (0.6613, 0.9982) 0.9286 (0.6613, 0.9982) 0.9286 (0.6613, 0.9982) 0.9286 (0.6613, 0.9982) 0.9286 (0.6613, 0.9982) 0.9286 (0.6613, 0.9982)
Specificity (95% CI) 1.0000 (0.8972, 1.0000) 1.0000 (0.8972, 1.0000) 1.0000 (0.8972, 1.0000) 1.0000 (0.9000, 1.0000) 1.0000 (0.9000, 1.0000) 1.0000 (0.9000, 1.0000)
Sum (sensitivity + specificity) 1.9286 1.9286 1.9286 1.9286 1.9286 1.9286
BIE = blinded image examination majority read; CI = confidence interval; REF = PET imaging brain reference region; SoT = standard of truth, SUVR = standard uptake value ratio. Refer to [32] for a discussion of
agreement between readers.





















Table 10 Sensitivity, specificity, and exact 95% CI for each SUVR type/pathology SoT combination in retrospective vs. prospective studies for all 4 studies
combined
Cerebellum REF Pons REF
Pathology SoT Ipsilateral Contralateral Composite Ipsilateral Contralateral Composite
4G8
Retrospective
Sensitivity (95% CI) 1.0000 (0.3976, 1.0000) 1.0000 (0.3976, 1.0000) 0.5000 (0.0676, 0.9324) 1.0000 (0.3976, 1.0000) 0.7500 (0.1941, 0.9937) 0.7500 (0.1941, 0.9937)
Specificity (95% CI) 0.6000 (0.3605, 0.8088) 0.7500 (0.5090, 0.9134) 0.9000 (0.6830, 0.9877) 0.4762 (0.2571, 0.7022) 0.6667 ()0.4303, 0.8541 0.6667 (0.4303, 0.8541)
Sum (sensitivity + specificity) 1.6000 1.7500 1.4000 1.4762 1.4167 1.4167
Prospective
Sensitivity (95% CI) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000) 0.8000 (0.2836, 0.9949) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000)
Specificity (95% CI) 0.6471 (0.3833, 0.8579) 0.5882 (0.3292, 0.8156) 0.8235 (0.5657, 0.9620) 0.5294 (0.2781, 0.7702) 0.6471 (0.3833, 0.8579) 0.5882 (0.3292, 0.8156)
Sum (sensitivity + specificity) 1.6471 1.5882 1.6235 1.5294 1.6471 1.5882
Bielschowsky
Retrospective
Sensitivity (95% CI) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000) 1.0000 (0.4782, 1.0000)
Specificity (95% CI) 0.8750 (0.6165, 0.9845) 0.8750 (0.6165, 0.9845) 0.9375 (0.6977, 0.9984) 0.7647 (0.5010, 0.9319) 0.8824 (0.6356, 0.9854) 0.8824 (0.6356, 0.9854)
Sum (sensitivity + specificity) 1.8750 1.8750 1.9375 1.7647 1.8824 1.8824
Prospective
Sensitivity (95% CI) 1.0000 (0.2924, 1.0000) 1.0000 (0.2924, 1.0000) 1.0000 (0.2924, 1.0000) 1.0000 (0.2924, 1.0000) 1.0000 (0.2924, 1.0000) 1.0000 (0.2924, 1.0000)
Specificity (95% CI) 0.9091 (0.5872, 0.9977) 0.9091 (0.5872, 0.9977) 0.9091 (0.5872, 0.9977) 0.9091 (0.5872, 0.9977) 1.0000 (0.7151, 1.000) 0.8182 (0.4822, 0.9772)
Sum (sensitivity + specificity) 1.9091 1.9091 1.9091 1.9091 2.0000 1.8182
Thioflavin S
Retrospective
Sensitivity (95% CI) 0.8571 (0.4213, 0.9964) 0.8571 (0.4213, 0.9964) 1.0000 (0.5904, 1.0000) 0.8571 (0.4213, 0.9964) 0.8571 (0.4213, 0.9964) 0.8571 (0.4213, 0.9964)
Specificity (95% CI) 1.0000 (0.8235, 1.0000) 0.9474 (0.7397, 0.9987) 0.8947 (0.6686, 0.9870) 0.7000 (0.4572, 0.8811) 0.9000 (0.6830, 0.9877) 0.9000 (0.6830, 0.9877)
Sum (sensitivity + specificity) 1.8571 1.8045 1.8947 1.5571 1.7571 1.7571
Prospective
Sensitivity (95% CI) 0.5000 (0.0126, 0.9874) 1.0000 (0.1581, 1.0000) 1.0000 (0.1581, 1.0000) 1.0000 (0.1581, 1.0000) 1.0000 (0.1581, 1.0000) 1.0000 (0.1581, 1.0000)
Specificity (95% CI) 0.9231 (0.6397, 0.9981) 0.8462 (0.5455, 0.9808) 0.7692 (0.4619, 0.9496) 0.8462 (0.5455, 0.9808) 0.9231 (0.6397, 0.9981) 0.7692 (0.4619, 0.9496)

























Sensitivity (95% CI) 1.0000 (0.5407, 1.0000) 1.0000 (0.5407, 1.0000) 1.0000 (0.5407, 1.0000) 1.0000 (0.5407, 1.0000) 1.0000 (0.5407, 1.0000) 1.0000 (0.5407, 1.0000)
Specificity (95% CI) 1.0000 (0.8316, 1.000) 0.9500 (0.7513, 9987) 1.0000 (0.8316, 1.0000) 0.8095 (0.5809, 0.9455) 0.8571 (0.6366, 0.9695) 1.0000 (0.8389, 1.000)
Sum (sensitivity + specificity) 2.0000 1.9500 2.0000 1.8095 1.8571 2.0000
Prospective
Sensitivity (95% CI) 0.8750 (0.4735, 0.9968) 1.0000 (0.6306, 1.0000) 1.0000 (0.6306, 1.0000) 0.8750 (0.4735, 0.9968) 1.0000 (0.6306, 1.0000) 0.8750 (0.4735, 0.9968)
Specificity (95% CI) 1.0000 (0.7684, 1.000) 1.0000 (0.7684, 1.0000) 1.0000 (0.7684, 1.0000) 0.9286 (0.6613, 0.9982) 0.9286 (0.6613, 0.9982) 1.0000 (0.7684, 1.0000)
Sum (sensitivity + specificity) 1.8750 2.0000 2.0000 1.8036 1.9286 1.8750
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eral study limitation that there was a clear cut difference
between the retrospective and prospective studies in the
size of the VOI assessed. We acknowledge the general
limitation that our data were not analyzed without the
partial volume correction.
The largest ROC AUC for the combination of SUVR
type and pathology SoT (4 studies combined) was for
composite-cerebellum SUVR/overall pathology SoT, the
most inclusive measure for imaging and the most com-
prehensive measure for pathology, respectively. ROC
AUCs for composite-cerebellum/and contralateral-pons/
Bielschowsky silver were nearly as large.
Based on the sum of sensitivity and specificity, BIE
was a better tool for predicting the Bielschowsky path-
ology findings than was quantitation with SUVR (in 6 of
the 6 SUVR/SoT pairs) but very similar to both quanti-
tation with SUVR and BIE using the overall pathology
judgment (i.e., high sensitivity and high specificity); the
converse was true for thioflavin S (less sensitive and
similarly specific) and 4G8 (substantially less sensitive
and usually more specific). Overall, based on the sum of
sensitivity and specificity, BIE and quantitation with
SUVR appeared to be tied.
No particular advantage to using one SUVR reference
region over the other (i.e., cerebellum or pons) was
apparent. However, for all SUVR types, SUVR cut-off
criteria using pons as the reference region were unex-
pectedly found to be less than 1. From the observed
optimal cut-off values of approximately 0.4 (pons as
reference region) and approximately 1.2 (cerebellum as
reference region) in this set of iNPH patients, one would
predict that on average, much more Aβ was deposited in
the pons than in the cerebellum. Whereas in AD, enough
Aβ for detection with tracer does not appear in the cere-
bellum or pons until Thal Phase 5 [37]. The significance
of this finding will need to be clarified in future research.
We should note that a post-hoc Spearman correlation
analysis was performed between cognitive status (Mini-
Mental State Examination [MMSE] scores, for which indi-
vidual subject values were previously published [32]), and
measures for all of the pathologic markers of amyloid,
including Bielschowsky, 4G8, thioflavin S, and overall
pathology judgment. No statistically significant correlation
was found, consistent with previous results that found no
significant correlation between an imaging marker for
amyloid load ([11C]PIB binding potential with PET) and
MMSE [46].
While neocortical pathological Aβ changes in affected
iNPH patients are similar to those in AD, and it is
tempting to apply findings from one condition to the
other, it is important to recognize that our understand-
ing of the molecular biology of amyloid is incomplete
[47]. We biopsied only cortical samples for use as ourSoT. While a reduction in brain tissue is characteristic
of both AD and iNPH, the reduction is due to atrophy
in AD, whereas the sulci are less enlarged relative to the
degree of ventricular dilatation in iNPH. However, the
fact that the overall pathology SoT fared so well in the
results may indicate that neocortical areas where amyl-
oid was present in our iNPH patients might have been
mimicking where Aβ pathological changes are seen in
AD, i.e., widespread vs. focal. Others confirm the validity
of diagnosis from a single cerebral biopsy sample [48].
To put the 4G8 antibody data into context, variable
processing of the membrane-bound amyloid precursor
protein (APP) produces Aβ and other APP fragments
including p3 [47]. Aβ is a 39-43 amino-acid peptide; the
4G8 antibody detects amino acids 17-23 [49] or 17-24
[37]. The morphology of deposits in AD brain detected
with 4G8 have been described with photomicrographs in
exquisite detail as fleecy (fine fibrillar [49]), lake-like,
and subpial band-like amyloid; diffuse and cored pla-
ques; and core-only (burnt-out [50]) plaques, as well as
white matter plaques; some of which types are further
sub-divided into neuritic and non-neuritic [51]. From
neocortex (Thal Phase 1), Aβ as detected using silver
stain and 4G8 appears progressively over time in specific
connected brain structures in an ordered anterograde
sequence [51,37].
Ikonomovic et al. demonstrated co-localization in an
AD brain of 6-CN-PiB (thioflavin T derivative) and thio-
flavin S to cored plaques and core-only plaques in tem-
poral cortex. Thioflavin S was not as selective and also
stained numerous neurofibrillary tangles in this region,
whereas 6-CN-PiB detected only an occasional isolated
tangle [22].
Silver staining and IHC for Aβ provide complementary
information. Silver, which stains both plaques and tangles
(which appear in neuritic plaques), renders stable and
reproducible results [52] and is recommended for quanti-
tation of neuritic plaques [38,43]. However, ‘argyrophilia’ is
not a homogeneous phenomenon with respect to amyloid
[51], and other subtle lesion-dependent variations between
silver methods have been described [52].
While the newest NIA-AA criteria for the neuropatho-
logic assessment of AD [38] also recommend IHC for
‘Aβ score’ (not plaque count) and refer to Thal [37], the
NIA-AA criteria stop short of specific Aβ IHC reagent
recommendations. Technical uncertainties with respect
to Aβ IHC standardization may preclude its use as a
standard for neuropathologic diagnosis, at least when
deposits are quantified as with histological diagnostic
criteria for AD [52]. For the neuropathologic changes of
AD, the new criteria recognize the qualitative importance
of the location and morphology of Aβ deposits as separate
and different from quantification by neuritic plaque
counts as in the CERAD scheme [38] or, by extension, as
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this study of iNPH cortical biopsies.
Spillantini et al. reported finding “a substantial increase
in the number of stained structures and the intensity of
staining” with 4G8 after pre-treatment with formic acid
[53], although data relative to no pre-treatment were
not shown. Shankar et al. believe that formic acid solu-
bilizes insoluble Aβ plaque cores isolated from human
AD brains and releases their constituent dimers and
monomers [54].
Plaques, composed largely of fibrillar Aβ, are dynamic
structures and likely act as local reservoirs of smaller
diffusable Aβ oligomers thought to be in equilibrium
with plaques [55]. Disruption of the electrophysiological
and microanatomical correlates of memory formation
(i.e., inhibition of long-term potentiation, facilitation
of long-term depression, reduced dendritic spine density,
synapse loss) are associated with the smaller, soluble Aβ
species [55], which are suspected of eventually [56] tipping
the gain-of-toxic-function [47] past steady-state in favor of
Aβ conglomeration and towards subsequent downstream
events. Importantly, this paradigm provides that plaques
may be present in cognitively (i.e., phenotypically) normal
individuals. Clinically identifying patients on this cusp
(cognitively normal/abnormal) and monitoring their dis-
ease progression (i.e., locating amyloid plaques in living
patients) is of tremendous relevance and urgent import-
ance to the testing of drugs that exploit the molecular
biology of Aβ for the treatment of AD.
In this study, we found that while the numbers of FN
and FP results were low (lowest for the overall pathology
SoT), for each of the 3 stains separately, the proportions
of patients with FP was substantially greater than the
proportions of patients with FN. Interestingly, in our ex-
perience based on a large autopsy study of [18F]fluteme-
tamol (68 brains, 43 Aβ positive, 25 Aβ negative) [report
in process], cases with sparse to moderate diffuse and
neuritic cortical plaques (Bielschowsky silver stain) may
lead to FN or FP PET readings (similar to those dis-
cussed in a recent review [57]). This ‘cusp’ phenomenon
may reflect the (currently unsettled) rest of the story of
the molecular biology of Aβ, what triggers and perpetu-
ates its neuronal anterograde trek [51,37] and under
what conditions (including the inflammatory component
of the pathology outside the scope of this report), and
what determines the point at which the recognizable
phenotype becomes apparent (i.e., the presumed point of
irreversible functional damage).
The 4G8 antibody has been used before in association
with amyloid PET ligand uptake [33,27]. The 4G8
component of our analysis can be interpreted both in
an isolated manner and in context. We questioned
the acceptability of pooling the 4G8 data from Study
A (obtained using an antibody dilution of 1:500) withthat from Studies B, C, and D (obtained using an
antibody dilution of 1:100). We noticed that Clark et al.
used 4G8 at a dilution of 1:2000 and we think reported
similar correlations (the use of Bonferroni ρ was unclear)
to what we previously reported for our pooled data (using
Pearson’s r) [32] in their [18F]florbetapir PET autopsy
study in subjects with and without AD or other age-
related pathologies [58,33]. And, Thal [49,37] and Braak
[59] used a dilution of 1:5000. In a systematic inter-
laboratory study, Alafuzoff et al. recommended that in
order to achieve reproducible results with 4G8 IHC, a
dichotomized assessment (they suggested present/absent)
rather than quantification should be applied [60]. Our raw
data showed that in Study A 4/7 biopsy samples had 4G8
present; in Studies B, C, and D, respectively, 6/9, 13/15,
and 16/16 biopsy samples had 4G8 present. Given the
small sample sizes, it is impossible to know how different
‘4G8 present/absent’ in our studies truly was, and there-
fore whether or not pooling of data on this basis is
indicated.
Our data showed that the 4G8 SoT did not perform as
well as the other SoTs in terms of the sum of sensitivity
and specificity; it showed good sensitivity and poor
specificity (indicating too many FP). Tissue preparation
may have been the reason for this, in that the threshold
for abnormal may not have been optimized. If the
threshold for abnormal were set lower than the 2.5% we
used, sensitivity would have decreased and specificity
would have increased. The fact that the 4G8 dichotom-
ous assessment did not match the overall pathology SoT
in many cases (i.e., 4G8 resulted in the most overall
pathology misclassifications) supports the interpretation
that the selected threshold was not optimal.
In a separate analysis (Study C) of iNPH patients
included in this pooled analysis and who also underwent
[11C]PiB PET imaging, ipsilateral, contralateral, and com-
posite SUVRs for both [18F]flutemetamol and [11C]PiB
correlated significantly with Aβ biopsy specimen levels
evaluated by 4G8, thioflavin S, and Bielschowsky silver
stain [30]. Our findings using the pooled [18F]flute-
metamol data in iNPH patients are also consistent with
findings for [18F]florbetapir where a correlation was shown
between PET brain labeling and grey matter plaque density
not only by 4G8 as alluded to above, but also as measured
by silver stain at autopsy in subjects with and without AD
or other age-related pathologies [58,33]. To our knowledge,
no biopsy or autopsy data for [18F]florbetaben have been
published yet.
Whereas our study was limited by the logistical con-
straints associated with the collection of comparatively
primitive neuropathologic data from clinical trials at mul-
tiple sites in the setting of rapidly changing (increasingly
refined) pathologic diagnostic criteria, we propose that
an ideal experiment might improve upon a similar basic
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the following elements: multiple patients with AD and
brain [18F]flutemetamol imaging near life’s end, followed
by post mortem examination of adjacent sections treated
with cyano-flutemetamol vs. e.g., IHC for selected Aβ
epitopes and tau epitopes (plus routine conventional
staining), with the Aβ and neurofibrillary tangle pathology
results described according to current nomenclature for
neuropathologic changes of AD [38]. Other desirable ex-
perimental elements include a selected battery of sections
of brains associated with all phases of AD severity, sec-
tions thick enough to allow confocal microscopy through
entire cells, collection of information with respect to indi-
vidual genetic risk association factors, thorough history
and timeline of medical conditions with any inflammatory
component, duration of cognitive impairment, and results
of recent neuropsychiatric assessments. The importance
of careful archiving of tissue samples and associated pa-
tient data to test for future findings cannot be overstated.
Paradoxically, owing to the relative rarity of appropriate
post mortem handling and disposition for these purposes,
the human brain may be as valuable an asset in death as it
is in life.
The performance characteristics and diagnostic efficacy
of the Aβ ligands when used alone, and more recently
when used with other imaging modalities (e.g., structural
MRI and fluorodeoxyglucose PET) [e.g., 42,61] or in con-
junction with the assessment of the well known AD risk
variant of apolipoprotein E (ε4 allele) [e.g., 62], have been
described in over a decade of literature. ApoE type has not
yet added clinically useful diagnostic information in con-
junction with imaging; however, algorithms which include
multiple biomarkers have been clearly shown to increase
the power of studies and reduce the number of patients
required to demonstrate the statistical significance of
findings [61] and are encouraged by the Food and Drug
Administration [63] and the Alzheimer’s Disease Neuro-
imaging Initiative (http://www.nia.nih.gov/research/dn/
alzheimers-disease-neuroimaging-initiative-adni), which
freely shares data. While we did not pre-specify the collec-
tion any CSF biomarker data in our 4 clinical trials (and
ApoE genotype was published for only 18 subjects in our
pooled dataset [31]), the relationship of certain CSF
biomarkers to brain biopsy findings was recently described
for a large series of patients (53 iNPH, 26 AD, and 23
other) at Kuopio University in Finland; quantified biopsy
Aβ load showed a negative correlation with both ventricu-
lar and lumbar CSF Aβ42 while levels of Aβ38 and Aβ40
showed no correlation [64]. In the near future we hope to
see clinical imaging with Aβ ligands combined with
assessments of other recently identified AD risk genes
(up to and including IHC for their protein products
at autopsy) such as for specific variants of clusterin
(CLU, Apo J), complement component receptor 1 (CR1),phosphatidylinositol binding clathrin assembly protein
(PICALM) [61], until a more powerful algorithm is
achieved that will almost certainly inform the identity of
one or more useful drug targets (drugs) for the slowing,
prevention, and/or arrest of this ultimately devastating
pathology.
In summary, both quantitative assessment and BIE of
[18F]flutemetamol images in this series of iNPH patients
showed good agreement with cortical biopsy histopath-
ology. The primary diagnostic effectiveness (as measured
by ROC AUC, Youden index, and sum of sensitivity and
specificity) for [18F]flutemetamol PET was best when the
composite SUVR measure using cerebellum as the refer-
ence region was paired with the overall pathology SoT.
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